FDA

Bart Peterson, JD, Senior Vice President for Corporate Affairs and Communications at Eli Lilly , and the keynote speaker of the Research!America’s National Research Health Forum talked with Medscape about the future of research and drug development, and whether cooperation between industry and the US Food and Drug Administration (FDA) can ever truly exist. To see the interview, click here .
By Robert J. Hariri, MD, PhD, Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics . Medical innovation is the source of dramatic improvements in the quality and length of life and also creates enormous value for society and the economy at large. For example, in 1900, the average U.S. life expectancy was 49 years. Today, it is 79. It is estimated by 2040, U.S. life expectancy will reach 85 years. This is primarily the result of innovation in medicine and improvements to public health. New medical treatments accounted for 45 percent of the increase in U.S. life expectancy between 1960 and 1997 and for nearly three-quarters of the increase in U.S life expectancy in...
By Robert J. Hariri, MD, PhD, Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics . Medical innovation is the source of dramatic improvements in the quality and length of life and also creates enormous value for society and the economy at large. For example, in 1900, the average U.S. life expectancy was 49 years. Today, it is 79. It is estimated by 2040, U.S. life expectancy will reach 85 years. This is primarily the result of innovation in medicine and improvements to public health. New medical treatments accounted for 45 percent of the increase in U.S. life expectancy between 1960 and 1997 and for nearly three-quarters of the increase in U.S life expectancy in...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...
Dear Research Advocate: Although Congress officially returns next week, many Members are back in Washington as the debate about the crisis in Syria commands center stage. Members also face looming fiscal deadlines, with only nine legislative days scheduled in September to act on those and a large backlog of other legislation. Given all this, it is not hard to predict how Congress will handle the long- or short-term budget resolutions, debt ceiling, the future of sequestration, tax and entitlement reform, and a myriad of other interconnected items: They will put off decision-making. Thus a continuing resolution (“CR”), extending FY13 budgets, looks likely, once again kicking the can down the...
John Eng, MD, was recently named as the latest winner of the Golden Goose Awards. Eng is the second winner announced in 2013, and others will be named in the coming weeks. The Golden Goose Award was created last year to celebrate researchers whose seemingly odd or obscure federally funded research turned out to have a significant, positive impact on society. Eng, a one-time researcher with the Veterans Administration in New York City, discovered that the venom contained in the bite of a Gila monster ’€” a lizard native to the southwest U.S. and northwest Mexico ’€” had components that could aid diabetics. His research was funded by the VA and built on previous studies funded by the National...
John Eng, MD, was recently named as the latest winner of the Golden Goose Awards. Eng is the second winner announced in 2013, and others will be named in the coming weeks. The Golden Goose Award was created last year to celebrate researchers whose seemingly odd or obscure federally funded research turned out to have a significant, positive impact on society. Eng, a one-time researcher with the Veterans Administration in New York City, discovered that the venom contained in the bite of a Gila monster ’€” a lizard native to the southwest U.S. and northwest Mexico ’€” had components that could aid diabetics. His research was funded by the VA and built on previous studies funded by the National...
Dear Research Advocate: The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word! One hundred and sixty five university presidents and chancellors, representing all 50 states, have called on the president and Congress to reverse the pending “innovation deficit” in an open...

Pages

Sidebar Quote

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco